Announcement • Sep 03

Caris Life Sciences Presents New Research Advancing Precision Oncology At the IASLC 2026 World Conference on Lung Cancer

Caris Life Sciences announced that researchers from Caris and the Caris Precision Oncology Alliance will present seven studies at the International Association for the Study of Lung Cancer 2026 World Conference on Lung Cancer, taking place September 12-15, 2026, in Seoul, South Korea. Caris research includes two mini oral presentations, one Poster Tour presentation and four poster presentations highlighting how comprehensive molecular profiling and AI-driven clinico-genomic analyses are advancing understanding of lung cancer biology, immunotherapy response and precision treatment strategies. Among the highlights are two mini oral presentations evaluating the impact of molecular and immune biomarkers in non-small cell lung cancer (NSCLC), a Poster Tour presentation examining transcriptomic subtypes in mesothelioma, and multiple studies leveraging the Caris clinico-genomic database to characterize genomic alterations, germline variants and treatment outcomes across thoracic malignancies. Analysis of 39,124 NSCLC samples found that MTAP-deleted tumors demonstrated higher PRMT5 expression. PRMT5-high/MTAP-deleted tumors were associated with the shortest overall survival across molecular subtypes. Among patients treated with immune checkpoint inhibitors, PRMT5-high/MTAP-deleted tumors were associated with shorter overall survival than PRMT5-high/MTAP-non-deleted tumors. PRMT5-high/MTAP-deleted tumors exhibited fewer CD8+ T-cells and other adaptive immune cells, suggesting a less favorable immune microenvironment. Evaluation of 43,261 NSCLC samples identified race- and ethnicity-associated differences in tumor genomics, immune microenvironment composition and clinical outcomes. Non-Hispanic Asian Pacific Islander patients demonstrated longer overall survival and fewer genomic alterations associated with resistance to immunotherapy than non-Hispanic White patients. Among immunotherapy-treated patients, non-Hispanic Black patients achieved longer survival despite a higher prevalence of immunotherapy-resistance molecular alterations. Transcriptomic analysis of 386 mesothelioma samples identified three biologically distinct clusters with unique molecular features and treatment outcomes. Chemotherapy, with or without bevacizumab, was associated with longer overall survival than immune checkpoint inhibitor therapy in two of the three clusters. If validated prospectively, the identified transcriptomic subtypes could help inform therapeutic decision-making and support a more personalized treatment approach for mesothelioma. Clinically relevant germline alterations were identified in 12.2% of 3,609 NSCLC patients. Frequently altered genes included MUTYH, CHEK2, ATM, BRCA2 and MITF. Among patients with linked tumor profiling, 45.8% of pathogenic, likely pathogenic or risk germline variants had a matching tumor variant. Clinically relevant germline alterations were identified in 13.4% of 149 small cell lung cancer patients with germline findings. Common alterations included MUTYH, APC, ATM, BRIP1 and CHEK2. In patients with linked tumor sequencing, more than half of pathogenic, likely pathogenic or risk germline variants had corresponding tumor variants. Among 588 RET-positive patients in the RET-MAP registry, 45 patients, or 7.7%, had non-lung adenocarcinoma (LUAD) histology. Non-LUAD histology was independently associated with shorter progression-free and overall survival following both selective RET inhibitors and first-line chemotherapy. Patients with large cell neuroendocrine carcinoma demonstrated a 75% objective response rate encouraging responses to selective RET inhibitors, with survival outcomes comparable to LUAD. Analysis of 34,022 NSCLC samples demonstrated that ITGB6 expression varies by histology and genomic context. High ITGB6 expression was associated with improved overall survival in lung adenocarcinoma but poorer outcomes in lung squamous cell carcinoma. These opposing prognostic associations support further evaluation of ITGB6 across molecularly defined NSCLC populations.

Caris Life Sciences, Inc. Stock Price

CAI Share Price Performance

CAI Community Narratives

The "Google Maps" of Cancer Biology – Data is the Moat

Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis

Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future

The "Google Maps" of Cancer Biology – Data is the Moat

Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future

Whole Genome And MRD Adoption Will Support A Stronger Long Term Thesis

Early Cancer Detection And MRD Leadership Will Deliver Outsized Long-Term Oncology Testing Upside

Trending Discussion

Recently Updated Narratives

Caris Life Sciences ($CAI): The "Big Data" Juggernaut Just Delivered a 94% Growth Surprise

CAI: Q2 Execution And Buybacks Will Support Balanced Future Prospects

CAI: Early Detection Sequencing Platform Will Drive Future Upside Potential

Snowflake Analysis

Caris Life Sciences, Inc. Key Details

About CAI

Recent CAI News & Updates

Investor sentiment improves as stock rises 17%

President notifies of intention to sell stock

Caris Life Sciences Presents New Research Advancing Precision Oncology At the IASLC 2026 World Conference on Lung Cancer

Recent updates

Caris Life Sciences, Inc. Competitors

Moderna

Natera

Teva Pharmaceutical Industries

IQVIA Holdings